Premier letter in support of Making Pharmaceutical Markets More Competitive Act (S. 1115) Last Updated: May 12, 2017
Filed under:
Print Friendly, PDF & Email

Today, Premier submitted a letter in support of the “Making Pharmaceutical Markets More Competitive Act” (S. 1115), introduced by Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO).

In the letter, Premier praised the legislation as an important first step toward creating a more competitive generic drug marketplace. Specifically, the bill requires HHS to publish a list of generic drugs where there are three or fewer competitors in the market, and allows manufacturers to request expedited FDA reviews for generic drug applications in these cases. In addition, we also supported the Act’s provisions for setting a clear timeframe for the FDA to act on facility inspections after an applicant has notified FDA that they have taken necessary actions to resolve an identified issue, which will go far to keep existing manufacturers in the market, quickly move through the remediation process and get drugs back into the national supply. Combined, these provisions are essential to addressing the generic drug price spikes that health systems and patients have experienced.

To view a full copy of the letter, please visit: